Small interfering RNA-mediated caveolin-1 knockout on plasminogen activator inhibitor-1 expression in insulin-stimulated human vascular endothelial cells

Acta Biochimica et Biophysica Sinica

Volumn 39, Issue 3, 2007, Pages 224-233

  Yang, Huiling ^a   He, Shuya ^a,b   Quan, Zhihua ^a   Peng, Weixia ^a   Yan, Bin ^a   Liu, Jianghua ^a   Wen, Fang ^a   Cao, Renxian ^a   Xu, Yangyan ^a   Wen, Gebo ^a   Hu, Weixin ^b  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Caveolin 1; Gene silencing; Insulin; Plasminogen activator inhibitor 1

Indexed keywords

CAV1 PROTEIN, HUMAN; CAVEOLIN 1; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRIMER DNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE;

BASE SEQUENCE; CAVEOLIN 1; CELL LINE; DNA PRIMERS; ENDOTHELIAL CELLS; GENE EXPRESSION; GENETIC VECTORS; HUMANS; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA INTERFERENCE; RNA, SMALL INTERFERING;

CHICKEN ANEMIA VIRUS;

EID: 33947218568     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2007.00270.x     Document Type: Article

References (23)

1. Gough SC, Rice PJ, McCormack L, Chapman C, Grant PJ. The relationship between PAI-1 and insulin resistance in newly diagnosed NIDDM. Diabet Med 1993, 10: 638-642
2. Vajo Z, Fawcett J, Duokworth WC. Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocr Rev 2001, 22: 706-717
3. Strack V, Hennige AM, Krutzfeldt J, Bossenmaier B, Klein HH, Kellerer M, Lammers R et al. Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms beta2 and theta. Diabetologia 2000, 43: 443-449
4. Deng HC, Ge Q, Liu JB, Li BR, Cheng W. Study on tyrosine kinase activity of insulin receptor in patients with type 2 diabetes mellitus. Chin J Endocrinol Metab 2006, 22: 30-33
5. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: Links, causes, and consequences. Arterioscler Thromb Vase Biol 2006, 26: 2200-2207
6. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS et al. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable heterooligomeric complex in vivo. J Biol Chem 1997, 272: 29337-29346
7. Xu YY, Yang HL, Tu J, He SY, Liao DF. Construction, identification and primary functional analysis of pcDNA3. 1/NT-GFP-Caveolin-1 and mutants plasmids. Chin J Arterioscler 2005, 13: 297-300
8. Yang HL, Xu YY, Luo DX, Liao DF. Caveolin-1 and the virus infection mediated by ACE2. Chin J Arterioscler 2006, 14: 353-358
9. Luo DX, Yang HL, Liao DF, Wan YP. Caveolae/caveolins and virus infection. Sheng Li Ke Xue Jin Zhan 2004, 35: 321-324
10. Xu YY, Yang HL, You Y, Qin L, Tu J. A reverse transcriptase polymerase chain reaction method improving the specific amplification of caveolin-1 gene Sequences. Chin J Med Genet 2006, 1: 59-62
11. Yang HL, Jiang HJ, Fang WY, Xu YY, Liao DF, He FC. High fidelity PCR with an off/on switch mediated by proofreading polymerases combining with phosphorothioate modified primers. Biochem Biophys Res Commun 2005, 328: 265-272
12. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296: 550-553
13. Milner J. RNA interference for treating cancers caused by viral infection. Expert Opin Biol Ther 2003, 3: 459-467
14. Burant CF, Treutelaar MK, Buse MG. Diabetes-induced structural and functional changes in insulin receptors from rat skeletal muscle. J Clin Invest 1986, 71: 260-270
15. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin1 gene-disrupted mice. Science 2001, 93: 2449-2452
16. Wei Y, LukashevME, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996, 273: 1551-1555
17. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 1997, 272: 30429-30438
18. Corely-Mastick C, Saltiel AR. Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. J Biol Chem 1997, 272: 20706-20714
19. Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation 2002, 106: 2372-2378
20. Banfi C, Eriksson P, Giandomenico G, Mussoni L, Sironi L, Hamsten A. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin, insights into the signaling pathway. Diabetes 2001, 50: 1522-1530
21. Parpal S, Karlsson M, Thorn H, Stralfors P. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J Biol Chem 2001, 276: 9670-9678
22. Venugopal J, Hanashiro K, Yang ZZ, Nagamine Y. Identification and modulation of a caveolae-dependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes. Proc Natl Acad Sci USA 2004, 101: 17120-17125
23. Ma GM, Halayko AJ, Stelmack GL. Effects of oxidized and glycated low-density lipoproteins on transcription and secretion of plasminogen activator inhibitor-1 in vascular endothelial cells. Cardiovase Pathol 2006, 15: 3-10